Cargando…

The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges

In 2013, physicians at the Honolulu Queen’s Medical Center (QMC) noticed that seven liver disease patients reported the use of OxyELITE Pro (OEP), a widely consumed dietary supplement (DS). Assuming a temporal association between OEP use and disease, they argued that OEP was the cause of this myster...

Descripción completa

Detalles Bibliográficos
Autores principales: Teschke, Rolf, Eickhoff, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848932/
https://www.ncbi.nlm.nih.gov/pubmed/27043544
http://dx.doi.org/10.3390/ijms17040476
_version_ 1782429450918428672
author Teschke, Rolf
Eickhoff, Axel
author_facet Teschke, Rolf
Eickhoff, Axel
author_sort Teschke, Rolf
collection PubMed
description In 2013, physicians at the Honolulu Queen’s Medical Center (QMC) noticed that seven liver disease patients reported the use of OxyELITE Pro (OEP), a widely consumed dietary supplement (DS). Assuming a temporal association between OEP use and disease, they argued that OEP was the cause of this mysterious cluster. Subsequent reexamination, however, has revealed that this QMC cohort is heterogeneous and not a cluster with a single agent causing a single disease. It is heterogeneous because patients used multiple DS’s and drugs and because patients appeared to have suffered from multiple liver diseases: liver cirrhosis, liver failure by acetaminophen, hepatotoxicity by non-steroidal antiinflammatory drugs (NSAIDs), resolving acute viral hepatitis by hepatitis B virus (HBV), herpes simplex virus (HSV), and varicella zoster virus (VZV), and suspected hepatitis E virus (HEV). Failing to exclude these confounders and to consider more viable diagnoses, the QMC physicians may have missed specific treatment options in some of their patients. The QMC physicians unjustifiably upgraded their Roussel Uclaf Causality Assessment Method (RUCAM) causality scores so that all patients would appear to be “probable” for OEP. However, subsequent RUCAM reassessments by our group demonstrated a lack of causality for OEP in the evaluated QMC cases. The QMC’s questionable approaches explain the extraordinary accumulation of suspected OEP cases at the QMC in Hawaii as single place, whereas similar cohorts were not published by any larger US liver center, substantiating that the problem is with the QMC. In this review article, we present and discuss new case data and critically evaluate upcoming developments of problematic regulatory assessments by the US Centers for Disease Control and Prevention (CDC), the Hawaii Department of Health (HDOH), and the Food and Drug Administration (FDA), as based on invalid QMC conclusions, clarifying now also basic facts and facilitating constructive discussions.
format Online
Article
Text
id pubmed-4848932
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48489322016-05-04 The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges Teschke, Rolf Eickhoff, Axel Int J Mol Sci Review In 2013, physicians at the Honolulu Queen’s Medical Center (QMC) noticed that seven liver disease patients reported the use of OxyELITE Pro (OEP), a widely consumed dietary supplement (DS). Assuming a temporal association between OEP use and disease, they argued that OEP was the cause of this mysterious cluster. Subsequent reexamination, however, has revealed that this QMC cohort is heterogeneous and not a cluster with a single agent causing a single disease. It is heterogeneous because patients used multiple DS’s and drugs and because patients appeared to have suffered from multiple liver diseases: liver cirrhosis, liver failure by acetaminophen, hepatotoxicity by non-steroidal antiinflammatory drugs (NSAIDs), resolving acute viral hepatitis by hepatitis B virus (HBV), herpes simplex virus (HSV), and varicella zoster virus (VZV), and suspected hepatitis E virus (HEV). Failing to exclude these confounders and to consider more viable diagnoses, the QMC physicians may have missed specific treatment options in some of their patients. The QMC physicians unjustifiably upgraded their Roussel Uclaf Causality Assessment Method (RUCAM) causality scores so that all patients would appear to be “probable” for OEP. However, subsequent RUCAM reassessments by our group demonstrated a lack of causality for OEP in the evaluated QMC cases. The QMC’s questionable approaches explain the extraordinary accumulation of suspected OEP cases at the QMC in Hawaii as single place, whereas similar cohorts were not published by any larger US liver center, substantiating that the problem is with the QMC. In this review article, we present and discuss new case data and critically evaluate upcoming developments of problematic regulatory assessments by the US Centers for Disease Control and Prevention (CDC), the Hawaii Department of Health (HDOH), and the Food and Drug Administration (FDA), as based on invalid QMC conclusions, clarifying now also basic facts and facilitating constructive discussions. MDPI 2016-03-31 /pmc/articles/PMC4848932/ /pubmed/27043544 http://dx.doi.org/10.3390/ijms17040476 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Teschke, Rolf
Eickhoff, Axel
The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title_full The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title_fullStr The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title_full_unstemmed The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title_short The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges
title_sort honolulu liver disease cluster at the medical center: its mysteries and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848932/
https://www.ncbi.nlm.nih.gov/pubmed/27043544
http://dx.doi.org/10.3390/ijms17040476
work_keys_str_mv AT teschkerolf thehonolululiverdiseaseclusteratthemedicalcenteritsmysteriesandchallenges
AT eickhoffaxel thehonolululiverdiseaseclusteratthemedicalcenteritsmysteriesandchallenges
AT teschkerolf honolululiverdiseaseclusteratthemedicalcenteritsmysteriesandchallenges
AT eickhoffaxel honolululiverdiseaseclusteratthemedicalcenteritsmysteriesandchallenges